On January 12, the International Generic and Biosimilar Medicines Association (IGBA) announced that Vivian Fritelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa, will be the next IGBA Chair for 2022.  The IGBA represents manufacturers of generic and biosimilars medicines around the world, and “works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders.”  Mr. Frittelli expressed that he is “very pleased to take over the Chair of IGBA for the second time and look[s] forward to building upon the strong leadership of Sudarshan Jian.  Strengthened by the newly established CEO Advisory Committee, IGBA will be in a stronger position to expand its outreach to its mission, priorities and operations.”